{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:48:13Z","timestamp":1773809293358,"version":"3.50.1"},"reference-count":39,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T00:00:00Z","timestamp":1714867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The objective of this study was to describe the real\u2010world characteristics and clinical status of patients with psoriatic arthritis (PsA) currently prescribed ixekizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were drawn from the Adelphi PsA Plus Disease Specific Programme (DSP), a cross\u2010sectional survey conducted in the United States between September 2021 and March 2022. Rheumatologists provided data for their next five consulting patients currently receiving ixekizumab, including demographic and clinical characteristics, disease severity, treatment history, reasons for treatment choice, satisfaction with current treatment, and current and historic symptom burden. Patients voluntarily completed questionnaires, providing perceptional data on symptom burden and satisfaction with current treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 68 rheumatologists provided data on 275 patients with PsA, 90 of whom completed the voluntary questionnaire. Patients had been prescribed ixekizumab for a mean of 11.7 (SD 10.6) months. Clinical characteristics, disease severity, and symptom burden of patients with PsA improved significantly from ixekizumab initiation to the most recent consultation, including symptom burden, tender and swollen joint counts, and body surface area affected by psoriasis (all <jats:italic>P<\/jats:italic> &lt; 0.001). Both rheumatologists and patients were satisfied with ixekizumab treatment and reported improvements in pain and fatigue. Improvements were noted after more than three months of ixekizumab treatment duration and regardless of whether the patients had prior exposure to an advanced therapy or were treatment na\u00efve.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results indicate that ixekizumab was efficacious in the treatment of PsA in real\u2010world clinical practice, complementing efficacy data from randomized controlled clinical trials. The results of this study may assist rheumatologists and their patients in making informed treatment choices.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr2.11676","type":"journal-article","created":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T20:09:34Z","timestamp":1714939774000},"page":"440-449","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["<scp>Real\u2010World<\/scp> Treatment Patterns, Clinical Outcomes, and Symptom Burden in Patients With Psoriatic Arthritis Prescribed Ixekizumab in the United States"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8949-4198","authenticated-orcid":false,"given":"Sherry","family":"Rohekar","sequence":"first","affiliation":[{"name":"Western University  London Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1811-5370","authenticated-orcid":false,"given":"Aisha","family":"Vadhariya","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Ross","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Malatestinic","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Janos","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5626-3163","authenticated-orcid":false,"given":"Nicola","family":"Massey","sequence":"additional","affiliation":[{"name":"Adelphi Real World  Bollington United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7188-3221","authenticated-orcid":false,"given":"Megan","family":"Hughes","sequence":"additional","affiliation":[{"name":"Adelphi Real World  Bollington United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6750-2666","authenticated-orcid":false,"given":"Sarah","family":"Weatherby","sequence":"additional","affiliation":[{"name":"Adelphi Real World  Bollington United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Birt","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Sebba","sequence":"additional","affiliation":[{"name":"University of South Florida  Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.9592.1"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1468252"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.001"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22583"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3879"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40726"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"e_1_2_8_9_1","unstructured":"Eli Lilly and Company.Lilly's Taltz (ixekizumab) receives U.S. FDA approval for the treatment of active psoriatic arthritis. December 1 2017. Accessed March 2 2023.https:\/\/www.drugs.com\/newdrugs\/lilly\u2010s\u2010taltz\u2010ixekizumab\u2010receives\u2010u\u2010s\u2010fda\u2010approval\u2010active\u2010psoriatic\u2010arthritis\u20104656.html"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"e_1_2_8_12_1","unstructured":"TALTZ (ixekizumab) injection. Prescribing information.US Food and Drug Administration;2021. Updated March 2021. Accessed June 14 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125521s014lbl.pdf"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-222027"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215386"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2160196"},{"issue":"1","key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1136\/annrheumdis-2023-eular.4883","article-title":"Real\u2010life efficacy and safety of ixekizumab in a cohort of patients with psoriatic arthritis: a single\u2010center retrospective study","volume":"82","author":"Bellis E","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_17_1","first-page":"463","article-title":"Treatment with ixekizumab following secukinumab failure in patients with psoriatic arthritis: real\u2010life experience from a resistant population","volume":"15","author":"Berman J","year":"2021","journal-title":"Biologics"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00490-2"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/24755303211063841"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00584-8"},{"issue":"3","key":"e_1_2_8_21_1","first-page":"581","article-title":"Efficacy and safety of ixekizumab in psoriatic arthritis: a retrospective, single\u2010centre, observational study in a real\u2010life clinical setting","volume":"38","author":"Manfreda V","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1184028"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802457040"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S120101"},{"key":"e_1_2_8_26_1","volume-title":"Stata Statistical Software: Release 17","year":"2021"},{"key":"e_1_2_8_27_1","unstructured":"US Department of Health and Human Services.Summary of the HIPAA Privacy Rule.2003. Accessed August 17 2022.http:\/\/www.hhs.gov\/sites\/default\/files\/privacysummary.pdf"},{"key":"e_1_2_8_28_1","unstructured":"Health Information Technology for Economic and Clinical Health Act (HITECH) Act of 2009 42 USC sec 139w\u20104(0)(2) (February 2009)."},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/c2lbri"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000692"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1954500"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160275"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.12.013"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201199"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.09.019"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220865"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-215003"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3578-9"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-018-4195-x"}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11676","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T17:08:05Z","timestamp":1759424885000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.11676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,5]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1002\/acr2.11676"],"URL":"https:\/\/doi.org\/10.1002\/acr2.11676","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"value":"2578-5745","type":"print"},{"value":"2578-5745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,5]]},"assertion":[{"value":"2024-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}